[TJG]

Nice day today, now if folks will stay off the sell button before we close we could see .40... I wonder how many read my previous post and got a better understanding of how this delay in the results may not be as bad as most think it is...
My previous post:

Message in reply to:
I am pretty sure that the reason for the delay lies right here in the study itself. This is information on the Clinical Trials. Gov site and if this did occure, patient reconsent, then releasing the data would have to be pushed back as they await the results from those who re entered.

https://www.clinicaltrials.gov/study/NCT04538625?cond=Cancer%20Therapy-Related%20Diarrhea&rank=1

After completing the Stage I double-blind, placebo-controlled primary treatment phase, the subjects will have the option to remain on their assigned treatment arm and reconsented to enter into the Stage II extension phase. Reconsent will be required to enter into Stage II. For subjects who do not reconsent, visit 5 will be the last study visit.

[TJG]

I am pretty sure that the reason for the delay lies right here in the study itself. This is information on the Clinical Trials. Gov site and if this did occure, patient reconsent, then releasing the data would have to be pushed back as they await the results from those who re entered.

https://www.clinicaltrials.gov/study/NCT04538625?cond=Cancer%20Therapy-Related%20Diarrhea&rank=1

After completing the Stage I double-blind, placebo-controlled primary treatment phase, the subjects will have the option to remain on their assigned treatment arm and reconsented to enter into the Stage II extension phase. Reconsent will be required to enter into Stage II. For subjects who do not reconsent, visit 5 will be the last study visit.

[TJG]

Pre market investors saw FDA and the word approval in the just released PR and jumped on buying before the read the release itself... once it was discovered it was concerning dogs... they backed off... took it from .34 to .40 in a minute and a half then back to .34 in another min or so... just shows when news hits this will run very fast... in either direction depending on what the news is.

[TJG]

We can only hope that something comes real soon... they have two Oncology conferences coming up... one on tomorrow and one on the 7th... they have stated they want to present the findings at those conferences... so I am hoping for good news today

[oldstocks]

Any hints of news yet?

[TJG]

It's a Blind Phase III so the company has no idea what has taken place..... which I dont buy, they have a good idea as to how it was going... reason I say that is you dont book a Breast Cancer appearence in Texas and make it a point to say you will be presenting the results there as well.... if they did and this comes back as not so good, they will be forced to with draw from the conference.

if its not good, there will be a shit load of people withdrawing from this stock as well... I personally feel they will be good.

[SmellMyFinger]

My average on this sucks, but it could be 100x worse like some people.

[ATM123]

Opinion - News will be good ok worse for next week ?

[TJG]

Just a quick note for those who are following this.... SNGX closed the day yesterday at .55 at 7:30 they put out a PR that the FDA has cleared them for a Phase II trial for an Ulcer drug.... since the open it has shot up to $1.53 and has been halted due to excessive volatility, in other words its moving to fast... JAGX is waiting on results from a completed Phase III trial, and if its good then they will submit to the FDA for approval to go to market....

Now for me if a Phase 2 approval is granted, granted to just start the Phase II and the stock is up $1.14 cents... what happens to a stock that get expected Top Shelf results and is ready for FDA submission for public distribution... I have added, but then thats just me... Good Luck Everyone

[TJG]

Nice Green Day maybe a turn around is coming our way for the rest of this week. Hard to tell with this stock where it’s going After hours close was .3699 so .37 maybe we can see a return to .40 before the Phase III information drops

[oldstocks]

TD Ameritrade thinkorswim offers options on JAGX

[TJG]

E*Trade offers them

[Jujuman2003]

Hi, where do you guys buy options on Jagx? I don't see an options menu on RobinHood. Thanks!

[moneydreamer]

Well said!!!

[TJG]

Over the years I have talked to so many IR people with these company's and have implored them not to put time lines on results. I did the same with Peter the VP of Investor Relations with Jaguar.... simply say the end of the year is what I told him... when you give dates or timelines and they are missed for what ever reasons, people shit themselves and hit the sell button.

I can imagine that the people who sold at .33, 32 and down to .29 are already kicking themselves... Lisa said in the PR they intend to have the results ready for the San Antonio Breast Cancer conference... so I take that as her telling the company doing the results that she will pay the over time if needed to get them before December 7th... So I see no reason for the panic selling.

[moneydreamer]

100%Agreeeee no news good news have no idea who will sell at this point$$$ nothing happens overnight and we almost there good luck y’all $$$

[TJG]

Yes I think it is... as I said I got more... the other thing is there are only so many places to go and get your results certified and they like everyone get backed up...

[shurtha2000]

Didn't make sense to release results before Thanx-Giving -people just don't work this week everyone planning and prepping for travel and cooking

[TJG]

Ok thanks, I was able to pick up a few thousand more this morning, panic sellers, not sure if everyone understands how the results work on these. The company use an outside agency to compile all of the results... when its called a Blind review that means they do not have the ability to see or get information on it until its released to them and the public at the same time... if the company choses to unblind it then they must accept the results and can not go back and work on any issues prior to submission to the FDA.... always better to keep the results blinded so they can change any issues the FDA may have a concern with. In this case I am not concerned... as the company does get updates while the trial is in progress from the different hospitals and clinics that are giving it to patients,

[shurtha2000]

back to low .30's

[oldstocks]

Tj what is your take on todays news of delay
https://finance.yahoo.com/news/top-line-data-jaguar-health-133000419.html

We are getting hit with a hard drop.
Is this a common buying opportunity?

[oldstocks]

That link is out of date. Yahoo and TD have it much higher.
https://finance.yahoo.com/quote/JAGX/key-statistics?p=JAGX
50.76 million outstanding

[TJG]

The current OS is

Jaguar Health has 19.11 million shares outstanding.

You can find everything you need on them here
https://stockanalysis.com/stocks/jagx/statistics/

[ATM123]

How much is OS as of now...

[oldstocks]

I put my JAGX up for over $3.50 if it hit i will have profit. We will see. $6 would be better

[TJG]

Well if I am being perfectly honest I would say $6 to match the number on Yahoo and we were indeed have a good day....

Chart shows us that the 52 week low was .0021 on Oct 16 with volume of 18 million shares that day then 10 days later 0026 with three million shares.... now I dont have a problem with people taking profit, hell thats the name of the game.. but when we are one or two days away from them announcing the Phase III results and they have waited this long, the company has all but verbally said the results are going to be good... why sell today when its touched .51 and if the results are good who knows how high it will go... buy what the hell profit is profit and cant begrudge them for taking it.

[oldstocks]

JAGX doing good today :)

[moneydreamer]

You meant 5$ very soon$$$$

[TJG]

More like the dollar range, if this turns out to be as good a report as they have led us to believe by the time they apply for FDA approval in early 2024 it should be back to a buck and beyond.

[shurtha2000]

easy lay up see you in the .50's

[TJG]

We can only hope that they do not put the Phase III results out today... hate to see it get lost over a weekend, better to put it out on Monday and get as much out of it as they can before the market is closed on Thursday and Fridays trading is about 75% less then normal.

[TJG]

IT IS IMPARITIVE THAT ANYONE WHO IS IN OR THINKING OF GETTING IN READ THIS TRANSCRIPT As you read look for the read box that indicates the transcript moves to the next page. If the results are as good as it appears they will be then getting in at these prices is a Early Christmas Gift for everyone.

https://www.insidermonkey.com/blog/jaguar-health-inc-nasdaqjagx-q3-2023-earnings-call-transcript-1223794/#q-and-a-session

[TJG]

Inching towards .50 I like that it’s a slow climb up less likely to collapse on the same day

[TJG]

Hahaha good one "Sheldon" there is more interest in this today after the absorption of the information that you just posted... as it gets closer to the release time of the Phase III data I suspect we could be close to .50

[oldstocks]

Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(1.23) by 69.11 percent. This is a 95.7 percent increase over losses of $(8.83) per share from the same period last year. The company reported quarterly sales of $2.81 million which beat the analyst consensus estimate of $2.46 million by 14.35 percent. This is a 10.70 percent decrease over sales of $3.15 million the same period last year.
Write to Benzinga at [e-mail]

[TJG]

Not sure the results were better, as the revenue was below year over year.... they had a year over year loss due to the cost of the Phase III trial, those are very expensive... they have expanded R&D on two other trials... but not sure why you are asking What made the results better, since I cant find where anyone said they were... the only real thing I see is that they beat the previous quarter by 5% in quarterly revenue.

This companys success, like all bio techs, hangs on the Phase III results... if positive they will seek approval in early 2024 once approved then the door swings wide open for not only using crofelemer in the Cancer treatment sector but many other treatments of diarrhea. Being a Natural product brings in a whole new patient base.

They fail at the intended results and this is going to be decision time for JAGX... but then all bio tech stocks face that same Risk Reward when it comes to trials for their new drugs.

For anyone in or thinking of getting in, read the Q that was released yesterday. Read the pipeline products they are developing and the products that are in trials and the ones that are already approved and being sold. The whole purpose for JAGX is to build a portfolio of approved products and then sell it off. They are a developer of product they are not a distributor nor is it the goal of the company to become one. It is the company estimate that their line of products that should be ready for market in the middle of 2024 will have a total value close to $80,000,000. 00 This is based on past history of others that have performed the same business plan. Buying and holding JAGX for this pay out is the only reason I am here and have been here for a couple of years. This Phase III is the key to getting all of this started. While they wait for the ability to sell of their entire portfolio approval now will begin a steady flow of revenue that will take this to that $6 price target that is listed on Yahoo financial for JAGX

[oldstocks]

Did i read that right?
The estimated (1.23) and the results (.38)
That looks like the loss was a lot better than expected.
What was the key drivers that made the results better?

[TJG]

Q will be out very soon, hoping for a nice bump up from an increase in revenue... but as they say wish in one hand and shit in the other...see which one fills up first. LOL

Its out.. a slight increase of 5% over the previous Q and the Phase III still on target to be reported before Thanksgiving

[oldstocks]

Profit takers? The shorts had a better chance of taking profits. If what you stated works out well maybe them shorts will cover while taking huge losses when they get caught with there pants down,

Go go JAGX!
Let this rip past the 52 week high of $11.62
Burn them shorts!

[TJG]

Average volume on this is 3.5 million shares a day... we will get to just over a million today... which is an indication that sellers, buyers and shorters are all waiting to see what happens.

[TJG]

They will release the Q tomorrow as well as give a business update for past, present and future... This will set the tone for how the stock is going to perform going forward. Then comes the Phase III results sometime next week..... make or break 10 days ahead for this stock.

Also as I posted before I contacted the company concerning the share structure and here is the reply I got... pretty standard no information reply... neither good new nor bad really.

Peter Hodge

From:
[e-mail]
To:
Tom

Fri, Nov 10 at 6:21 PM

Hi Tom,



Thanks for the note. Per Jaguar’s Q2 2023 10-Q, there were 19,117,219 shares of voting common stock as of August 14, 2023. As announced, the company plans to file its Q3 2023 10-Q Tuesday of next week, which will list an updated share count.



Apologies, but I am not able to comment about any possible share selling or debt conversion activity that the company may or may not engage in in the future.



Best,

Peter



Peter Hodge

Vice President, Investor Relations, Business Development & Special Events

Jaguar Health, Inc.

[e-mail]

Headquarters:

200 Pine Street, Suite 400

San Francisco, CA, 94104

www.jaguar.health

[TJG]

I have contacted the company and hope to get a reply from the IR... want to know how much of these "news" sell offs are coming from the company / convertible debt. And are they about done or will it continue right up to and through the Phase III announcement See if I get a reply

[TJG]

Profit takers... clueless on when to sell and how to sell... when its moving up sell in to the ASK twits, not the BID

[TJG]

Indeed as we have said as we get closer to the release of the data from the Phase III trial the buying will pick up.... That and the release of the Q 3 financials next week should make for an interesting week.

[moneydreamer]

JAGX strong buy all over now$$$$

[oldstocks]

$JAGX News: Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium


https://finance.yahoo.com/news/breast-cancer-related-results-groundbreaking-133000713.html

[TJG]

This news is significant in many ways, but most off it gives investors the knowledge that a reverse stock split, if needed is still many months off. With the amount of things lined up between now and the May time line its easy to see why this will be a the minimum bid price and wall as being possibly close to the target price posted on Yahoo finance.

https://finance.yahoo.com/news/jaguar-health-receives-additional-180-152500312.html

Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

ACCESSWIRE· Jaguar Health, Inc.
Jaguar Health, Inc.
Wed, Nov 8, 2023, 9:25 AM CST4 min read

In This Article:
JAGX
+11.28%
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on November 8, 2023 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-day grace period, through May 6, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The Staff noted that the Company meets all other applicable requirements for initial and continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before May 6, 2024.

"We are pleased to have obtained additional time from Nasdaq to evidence compliance with the bid price requirement," Lisa Conte, Jaguar's president and CEO, said. "Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence. Top line results from this pivotal study are expected before Thanksgiving."


Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID for these debilitating conditions.

Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency (EMA) for both MVID and SBS with intestinal failure. The ODD programs in the U.S. and European Union qualify sponsors to receive potential incentives to develop therapies for the diagnosis, prevention, or treatment of rare diseases or conditions.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

Jaguar Health, Inc. (JAGX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Following
Quote Lookup
0.2910+0.0295 (+11.2811%)
At close: November 8 04:00PM EST
0.2870 -0.00 (-1.37%)
Pre-Market: 06:19AM EST

Previous Close 0.2615
Open 0.2693
Bid 0.0000 x 1300
Ask 0.0000 x 900
Day's Range 0.2650 - 0.2948
52 Week Range 0.2100 - 12.0000
Volume 2,854,006
Avg. Volume 4,065,266
Market Cap 5.642M
Beta (5Y Monthly) 1.72
PE Ratio (TTM) N/A
EPS (TTM) -7.9100
Earnings Date Nov 14, 2023
1y Target Est 6.00

[oldstocks]

Lisa Conte, Jaguar's president and CEO, said. "Our paramount near-term clinical activity is our Phase 3 pivotal OnTarget trial of Mytesi for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as chronic debilitating diarrhea, GI urgency, and GI incontinence. Top line results from this pivotal study are expected before Thanksgiving."

[TJG]

If things are going to turn around for this stock its going to start to happen next week... they have products that are out there in the pipeline being subscribed and sold, they have a lot coming up and the business side of the call should expound on that... then we wait for the results of the Phase III and that combined with a good Q report should see this begin to steadily move up

https://finance.yahoo.com/news/jaguar-health-hold-investor-webcast-133000038.html